TITLE

Warner Chilcott TL Allocates, Trades Up

AUTHOR(S)
Sheahan, Matthew
PUB. DATE
August 2010
SOURCE
High Yield Report;8/23/2010, Vol. 21 Issue 34, p19
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the move by Warner Chilcott to raise the size of its term loan (TL) for trading on August 25, 2010 from 1 billion U.S. dollars to 1.035 billion.
ACCESSION #
53160798

 

Related Articles

  • Banks Set OID for Warner $1.5B TLB. Kellerhals, Richard // High Yield Report;9/7/2009, Vol. 20 Issue 36, p24 

    The article reveals that the original issue discount (OID) for the 1.5 billion U.S. dollar term loan B tranche has been set by a bank consortium seeking a senior secured credit facility for Warner Chilcott. Particular focus is given to the spread of the term loan and its price structure. Banks...

  • Warner Chilcott Loan Trades Above Par. Kellerhals, Richard // High Yield Report;10/19/2009, Vol. 20 Issue 42, p8 

    The article reports on a 1.95 billion U.S. dollar term loan B for Warner Chilcott which sold at Libor plus 350 basis points and climbed past par to 100.25 cents. It is noted that the term loan was part of a 3.2 billion U.S. dollar credit facility that also consisted of a 1 billion U.S. dollar...

  • Warner Deal to Launch Soon. Kellerhals, Richard // High Yield Report;9/21/2009, Vol. 20 Issue 38, p21 

    The article reports on a 2.75 billion U.S. dollar credit facility for Warner Chilcott which is being prepared by a bank consortium. The facility includes a 1.5 billion U.S. dollar term loan B, a 1 billion U.S. dollar term loan A and a 250 million U.S. dollar revolver. Some banks in the...

  • Ireland's Warner Chilcott buys P&G's pharma business.  // TCE: The Chemical Engineer;Oct2009, Issue 820, p4 

    The article reports on the decision of Irish pharmaceuticals company Warner Chilcott to buy the pharmaceuticals business of Procter & Gamble in October 2009.

  • SWOT Analysis.  // Warner Chilcott Ltd. SWOT Analysis;Aug2009, p1 

    A company profile of Warner Chilcott Ltd., a specialty pharmaceutical company engaged in developing, manufacturing and marketing of branded prescription pharmaceutical products in women's healthcare and dermatology operating in the U.S. and Ireland, is presented. An overview of the company is...

  • FDA approved next-generation risedronate sodium.  // Endocrine Today;Nov2010, Vol. 8 Issue 11, p9 

    The article reports on the approval made by the U.S. Food and Drug Administration (FDA) on a next-generation, delayed-release formulation of risedronate sodium for managing postmenopausal osteoporosis manufactued by Warner Chilcott.

  • The biggest merger you didn't hear about today. Primack, Dan // Fortune.com;12/20/2013, p1 

    The article discusses reasons why Internet company Yahoo's acquisition of start-up firm Tumblr has gotten more online media attention than drug company Actavis' purchase of rival Warner Chilcott. The author observes that most people can more readily understand Tumblr's business than Warner...

  • REGIONAL REPORT: Charlotte.  // Business North Carolina;Jan2014, Vol. 34 Issue 1, p30 

    The article presents business updates in North Carolina as of January 2014. The city revealed plans that could make the Charlotte Douglas International Airport one of the largest sites of solar-power generation in the state. Weber Screwdriving Systems plans to move manufacturing operations in...

  • Pharma: Other News To Note.  // BioWorld Today;7/12/2013, Vol. 24 Issue 132, p9 

    This section offers pharmaceutical industry news briefs as of July 12, 2013. Swiss therapeutic products regulator Swissmedic has approved Eisai Co. Ltd.'s Zonegran (zonisamid) as a monotherapy for newly diagnosed epilepsy in adults. Galen US Inc. will acquire exclusive rights to market and sell...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics